Toronto, Ontario (PRWEB) June 10, 2013
The Hemostemix Group of Companies announced today the formation of its Scientific Advisory Board (the “Board”) and the addition of its first three members.
The Hemostemix Group is comprised of Hemostemix Ltd. (Hemostemix), a company incorporated in Israel with an operating research, development and manufacturing facility in Ness Ziona, Kwalata Trading Ltd. (“Kwalata”), registered in Cyprus, and the parent company Theravitae, Inc. (“TVI”) based in Toronto, Ontario, Canada (collectively the “Hemostemix Group” or “Group”).
The first three members of the Board to be announced are:
Dr. Heinz Redl
Heinz Redl, Ph.D. is the Chair-elect of the European Chapter of the Tissue Engineering and Regenerative Medicine International Society, head of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology and Associate Professor at the Vienna University of Technology. He is coordinator of the Austrian Cluster for Tissue Regeneration (together with the Medical University Vienna) with 5 branches – bone, cartilage, peripheral nerve, soft tissue (wound healing) and imaging - and also the CEO of the non-profit Trauma Care Consult.
Dr. Norman Wong
Norman C.W. Wong, M.D., F.R.C.P.(C) is a Fellow of The Royal College of Physicians of Canada and is currently a Professor in the Departments of Medicine, Biochemistry and Molecular Biology in the Faculty of Medicine at the University of Calgary. His previous roles include Associate VP Research and International, assistant Dean of research for the faculty of Medicine and as well as Director of the Libin Gene Therapy Unit. He has acted as a consultant to several leading pharmaceutical companies, including Eli Lilly, Merck Frost, GlaxoSmithKline, Solvay Pharmaceuticals and Abbott Laboratories.
Dr. Mark Zucker
Mark Jay Zucker, M.D., J.D., F.A.C.C., F.A.C.P. is Director of the Harvey and Georgina Weinstein National Heart Transplant Center at Newark Beth Israel Medical Center and Clinical Professor of Medicine at the University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J. Dr. Zucker graduated from Northwestern University with his medical degree and from Loyola University with a law degree. Prior to his current appointments, Dr. Zucker has served in faculty positions at Mount Sinai School of Medicine in New York and Loyola University Medical School in Illinois. He currently is Advisory Board Vice-Chair and on the Board of Directors for the New Jersey Organ & Tissue Sharing Network. He has been involved with heart and lung transplantation and mechanical circulatory support for over 25 years and has been a principal or co-investigator on more than 40 trials including trials of cell-based therapies such as the BioHeart myoblast trial and the ongoing Baxter RENEW trial.
“We are committed to having a world-class Scientific Advisory Board we can draw expertise from as we move forward with our strategy and particularly with the phase 2 trial of our cell therapy product for patients with critical limb ischemia recently cleared to proceed by Health Canada,” stated Hemostemix Group President Dr. Valentin Fulga. “Each of the three members announced today has followed our company and its technology for some time and we are very pleased they have agreed to join our SAB,” Fulga concluded.
Further announcements about additions to the Hemostemix Group’s Scientific Advisory Board are expected to be made in the near future.
About Hemostemix Ltd
Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (collectively, the “Hemostemix Group”). On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) (“Technical”) regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.
Read the full story at http://www.prweb.com/releases/2013Hemostemix/SAB/prweb10807580.htm.
Copyright©2012 Vocus, Inc.
All rights reserved